Table 1 Baseline characteristics
n = 531 | CAPOX n = 156 | FOLFOX n = 366 | Oxaliplatin DI > 80% n = 221 | Oxaliplatin DI ≤ 80% n = 310 | |
|---|---|---|---|---|---|
Age -median (IGR) | 62 (54 – 68) | 63 (55 – 68) | 60 (50 – 67) | 61 (55 – 68) | 62 (53 – 68) |
Age -mean (STD) | 60.3 (10.5) | 58.5 (10.8) | 61 (10.3) | 60.4 (9.7) | 60.1 (11) |
Age -range | 19 – 83 | 24 – 79 | 19 – 83 | 24 – 77 | 19 – 83 |
Sex – Female | 251 (47.3%) | 65 (41.7%) | 179 (48.9%) | 85 (33.9%) | 166 (66.1%) |
Sex – Male | 280 (52.7%) | 91 (58.3%) | 187 (51.1%) | 136 (48.6%) | 144 (51.4%) |
Median Follow-up (IQR) days | 1100 (937 – 1551) | 1030 (870.5—1104) | 1217 (973—1791) | 1168 (918—1552) | 1083 (960—1540) |
T0-2 | 60 (11.3%) | 10.9% | 11.5% | 13.7% | 9.7% |
T3 | 301 (56.7%) | 57.1% | 56.6% | 54.3% | 58.4% |
T4 | 166 (31.3%) | 31.4% | 31.1% | 31.7% | 31% |
N0 | 28 (5.3%) | 3.2% | 5.2% | 1.8% | 7.7% |
N1 | 314 (59.1%) | 56.4% | 60.7% | 62% | 57.1% |
N2 | 187 (35.2%) | 40.4% | 33.6% | 35.7% | 34.8% |
Deceased | 18.1% (96 events) | 18 (11.5%) | 75 (20.5%) | 29 (13.1%) | 67 (21.6%) |